Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith A Perez

Showing results (31-40 of 324) with videos related to

Pageof 33
Sort By:
The Oncologist|November 6, 2009
Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancerVivek Roy, Edith A Perez
Current Opinion in Oncology|October 12, 2011
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a reviewJacob Mathew, Edith A Perez
Cancer|October 19, 2011
Current and emerging targeted therapies for metastatic breast cancerEdith A Perez, Jean-Philippe Spano
Mayo Clinic Proceedings|June 2, 2009
Treatment options for breast cancer resistant to anthracycline and taxaneAlvaro Moreno-Aspitia, Edith A Perez
Clinical Therapeutics|October 8, 2009
Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trendsAlvaro Moreno-Aspitia, Edith A Perez
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
Molecularly targeted therapies for breast cancerTimothy J Hobday, Edith A Perez
Lancet (London, England)|August 30, 2008
Lack of publication bias related to results from trastuzumab studyEdith A Perez, Vera J Suman
Future Oncology (London, England)|March 25, 2006
Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancerAlvaro Moreno-Aspitia, Edith A Perez
Clinical Breast Cancer|November 10, 2005
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancerAlvaro Moreno-Aspitia, Edith A Perez
Seminars in Oncology Nursing|February 17, 2007
Managing high-risk breast cancerFrances M Palmieri, Edith A Perez
Pageof 33

Showing results (31-40 of 324) with videos related to

Sort By:
Pageof 33
The Oncologist|November 6, 2009
Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancerVivek Roy, Edith A Perez
Current Opinion in Oncology|October 12, 2011
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a reviewJacob Mathew, Edith A Perez
Cancer|October 19, 2011
Current and emerging targeted therapies for metastatic breast cancerEdith A Perez, Jean-Philippe Spano
Mayo Clinic Proceedings|June 2, 2009
Treatment options for breast cancer resistant to anthracycline and taxaneAlvaro Moreno-Aspitia, Edith A Perez
Clinical Therapeutics|October 8, 2009
Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trendsAlvaro Moreno-Aspitia, Edith A Perez
Cancer Control : Journal of the Moffitt Cancer Center|April 28, 2005
Molecularly targeted therapies for breast cancerTimothy J Hobday, Edith A Perez
Lancet (London, England)|August 30, 2008
Lack of publication bias related to results from trastuzumab studyEdith A Perez, Vera J Suman
Future Oncology (London, England)|March 25, 2006
Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancerAlvaro Moreno-Aspitia, Edith A Perez
Clinical Breast Cancer|November 10, 2005
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancerAlvaro Moreno-Aspitia, Edith A Perez
Seminars in Oncology Nursing|February 17, 2007
Managing high-risk breast cancerFrances M Palmieri, Edith A Perez
Pageof 33